Research LettersThe Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus
References (9)
JAMA Oncol
(2019)J Hepatol
(2019)J Am Coll Cardiol
(2017)Gut
(2020)
There are more references available in the full text version of this article.
Cited by (1)
Nucleo(s)tide analogue withdrawal in chronic hepatitis B virus infection: Beyond the HBsAg loss
2022, Digestive and Liver Disease
Conflicts of interest The authors disclose no conflicts.
Funding This project was supported in part by Gilead Sciences (IN-US-174-5740), and the facilities and resources of the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413), the Michael E. DeBakey Veterans Affairs Medical Center, and the Texas Medical Center Digestive Diseases Center (National Institute of Diabetes and Digestive and Kidney Diseases P30 DK 56338-10/15), Houston, Texas. Dr. Kim was supported by the National Institute of Diabetes and Digestive and Kidney Diseases T32 grant (DK083266). The views expressed in this article are those of the authors and do not necessarily represent the views of the funding institutions.
Published by Elsevier Inc. on behalf of the AGA Institute